Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ProShares Ultra Gold ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while ProShares Ultra Gold ETF trades at $44.81. The key difference: ProShares Ultra Gold ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | UGL | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $85.62 |
52-Week Low | $278.09 | $33.59 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
UGL, the ProShares Ultra Gold ETF, trades at $45.76, down 0.74% on the day, reflecting ongoing pressure in the gold market. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights gold's 25% decline from record highs amid Fed policy uncertainty and geopolitical tensions, though central bank buying provides some support. The ETF's leveraged structure amplifies daily gold price movements, impacting short-term performance.
The outlook for UGL hinges on gold price direction, with near-term risks from rising Treasury yields and inflation data. Opportunities exist if geopolitical tensions or dovish Fed shifts boost gold, but volatility remains high. Investors should note the ETF's decay risk from daily rebalancing in stagnant or volatile markets, making it more suitable for tactical plays than long-term holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
